Please Wait.....
Report
In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) & Region- Global Forecast to 2030
Market Report I 2025-05-09 I 740 Pages I MarketsandMarkets
The global In vitro diagnostics market is projected to reach USD 157,632.5 million by 2030 from USD 109,065.5 million in 2025, at a CAGR of 7.6% during the forecast period. This is due to the increasing global burden of chronic diseases such as diabetes, cardiovascular conditions, cancer, and infectious diseases (e.g., HIV, tuberculosis). Demand for faster results, decentralized testing, and home-based diagnostics are pushing growth in point-of-care (POC) testing devices, innovations such as high-throughput systems, lab-on-a-chip, next-generation sequencing (NGS), and POC diagnostics, and government and private sector investments in healthcare infrastructure, especially in developing economies, are improving access to diagnostic services.
The reagents & kits segment is expected to grow at the highest CAGR during the forecast period.
Based on the product, the in vitro diagnostics market is divided into reagents & kits, instruments, and data management software & services. In 2024, the reagents & kits segment grew at the highest CAGR in vitro diagnostics market. This is due to the growing number of tests across hospitals, labs, and home settings, the expansion of rapid and self-testing kits, especially for glucose, pregnancy, and infectious disease detection, the expansion of clinical laboratories, diagnostic chains, and POC testing environments increases reagent usage. Continuous product launches and regulatory approvals-such as CE-IVD marking and FDA clearances-are expanding the portfolio and accessibility of specialized test kits across various clinical applications.
The infectious diseases segment of the in vitro diagnostics market, by application, is expected to hold the largest market share during the forecast period.
Based on application, the in vitro diagnostics market is segmented into infectious diseases, oncology, endocrinology, cardiology, blood screening, genetic testing, autoimmune diseases, allergy diagnostic, drug monitoring & testing, bone & mineral disorders, coagulation testing, blood group typing, and other applications. The infectious disease segment accounts for the largest market share of the in vitro diagnostics market due to the continued prevalence of diseases such as HIV, hepatitis, and tuberculosis, and emerging threats such as Malaria and Mpox, the need for fast, accessible testing-especially in remote or resource-limited settings-has boosted the adoption of portable and easy-to-use IVD kits for infectious diseases, and technologies such as RT-PCR (Reverse transcription polymerase chain reaction) and syndromic panel testing enable accurate, high-throughput diagnosis of multiple pathogens, driving growth in hospital and lab settings.
Asia Pacific is expected to hold the highest CAGR in the in vitro diagnostics market during the forecast period.
The global in vitro diagnostics market is segmented into six major regions, namely, North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC Countries. Asia Pacific is estimated to grow at the highest CAGR during the forecast period. The IVD market in the Asia Pacific region is growing rapidly due to the increasing prevalence of communicable and non-communicable diseases, especially in highly populated countries such as China and India. These countries are seeing a rise in conditions such as diabetes, cancer, cardiovascular diseases, tuberculosis, and hepatitis. Concurrently, the aging population is driving the IVD market in the Asia Pacific region, especially in Japan, South Korea, and China. For instance, within China, 216.76 million people are aged 65 and above, or 15.4% of the population, a 2023 report by China's Ministry of Civil Affairs and the China National Committee on Aging stated. This trend is resulting in a growing demand for chronic disease monitoring and regular diagnostics. In an effort to increase local production and decrease the reliance on imports, regional governments are promoting the manufacture of diagnostic reagents, kits, and equipment locally, thus also fuelling the growth of the market.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1- 42%, Tier 2- 30%, and Tier 3- 28%
- By Designation: C-level- 46%, Director level- 23%, and Others- 31%
- By Region: North America- 23%, Europe- 45%, Asia Pacific- 28%, Latin America- 3%, Middle East & Africa- 0.5%, and GCC Countries- 0.5 %
Note 1: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.0 billion, Tier 2 = USD 1.0 billion to USD 10.0 billion, and Tier 3 =
Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
The major players operating in the in vitro diagnostics market include Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Hologic, Inc. (US), Bio-Rad Laboratories, Inc. (US), bioMerieux (France), Sysmex Corporation (Japan), Revvity (US), Becton, Dickinson and Company (US), Agilent Technologies, Inc. (US), Qiagen (Germany), DiaSorin S.p.A. (Italy), Grifols, S.A. (Spain), Werfen (Spain), and QuidelOrtho Corporation, (US) among others.
Research Coverage
This report studies the in vitro diagnostics market based on product & service, technology, specimen, site of testing, application, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to six major regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to gain a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.
This report provides insights on the following points:
- Analysis of key drivers (Increasing geriatric population and subsequent rise in chronic diseases, growing awareness of early disease diagnosis in emerging economies, emergence of rapid PoC technologies and rising adoption of automated analyzers, growing preference for personalized medicines), restraints (Unfavorable reimbursement scenario, stringent regulatory requirements, High cost of diagnostic equipment), opportunities (introduction of disease-specific biomarkers and tests, increasing significance of companion diagnostics, growth opportunities in developing countries, Improvements in immunoassay diagnostic technologies, digitalization trend), challenges (operational barriers, data privacy, and cybersecurity risks)
- Market Penetration: Complete knowledge of the spectrum of products presented by the major companies in the in vitro diagnostics market
- Product Development/Innovation: Comprehensive understanding of the forthcoming trends, research and development initiatives, and product launches within the in vitro diagnostics market
- Market Development: Complete knowledge about profitable developing regions
- Market Diversification: Exhaustive knowledge of new goods, expanding geographies, and current changes in the in vitro diagnostics industry helps to diversify the market
- Competitive Assessment: Comprehensive evaluation of market segmentation, development plans, income analysis, and goods of the top market participants
1 INTRODUCTION 57
1.1 STUDY OBJECTIVES 57
1.2 MARKET DEFINITION 57
1.3 STUDY SCOPE 58
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 58
1.3.2 INCLUSIONS AND EXCLUSIONS 59
1.3.3 YEARS CONSIDERED 60
1.4 CURRENCY CONSIDERED 60
1.5 STAKEHOLDERS 61
1.6 SUMMARY OF CHANGES 61
2 RESEARCH METHODOLOGY 62
2.1 RESEARCH DATA 62
2.1.1 SECONDARY RESEARCH 63
2.1.1.1 Key data from secondary sources 64
2.1.2 PRIMARY DATA 65
2.1.2.1 Primary sources 65
2.1.2.2 Key data from primary sources 66
2.1.2.3 Key industry insights 67
2.2 MARKET SIZE ESTIMATION 68
2.2.1 BOTTOM-UP APPROACH 69
2.2.1.1 Approach 1: Company revenue estimation approach 69
2.2.1.2 Approach 2: Presentations of companies and primary interviews 70
2.2.1.3 Growth forecast 70
2.2.2 TOP-DOWN APPROACH 71
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 72
2.4 MARKET SHARE ANALYSIS 73
2.5 RESEARCH ASSUMPTIONS 73
2.5.1 PARAMETRIC ASSUMPTIONS 73
2.5.2 GROWTH RATE ASSUMPTIONS 74
2.6 RESEARCH LIMITATIONS 74
2.7 RISK ASSESSMENT 74
3 EXECUTIVE SUMMARY 75
?
4 PREMIUM INSIGHTS 82
4.1 IN VITRO DIAGNOSTICS MARKET OVERVIEW 82
4.2 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY, 2024 83
4.3 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 84
4.4 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC MIX 84
4.5 IN VITRO DIAGNOSTICS MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS 85
5 MARKET OVERVIEW 86
5.1 INTRODUCTION 86
5.2 MARKET DYNAMICS 86
5.2.1 DRIVERS 87
5.2.1.1 Increasing geriatric population and subsequent rise in chronic diseases 87
5.2.1.2 Growing awareness of early disease diagnosis in emerging economies 88
5.2.1.3 Emergence of rapid PoC technologies and rising adoption of automated analyzers 89
5.2.1.4 Growing preference for personalized medicines 89
5.2.2 RESTRAINTS 90
5.2.2.1 Unfavorable reimbursement scenario 90
5.2.2.2 Stringent regulatory requirements 90
5.2.2.3 High cost of diagnostic equipment 92
5.2.3 OPPORTUNITIES 92
5.2.3.1 Introduction of disease-specific biomarkers and tests 92
5.2.3.2 Increasing significance of companion diagnostics 93
5.2.3.3 Growth opportunities in developing countries 94
5.2.3.4 Improvements in immunoassay diagnostic technologies 95
5.2.3.5 Digitalization trend 96
5.2.4 CHALLENGES 96
5.2.4.1 Operational barriers 96
5.2.4.2 Data privacy and cybersecurity risks 97
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 98
5.4 PRICING ANALYSIS 98
5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER 98
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION 100
5.4.3 AVERAGE SELLING PRICE TREND, BY PRODUCT 100
5.5 VALUE CHAIN ANALYSIS 102
5.5.1 RESEARCH & DEVELOPMENT 102
5.5.2 RAW MATERIAL SUPPLIERS 102
5.5.3 MANUFACTURING 102
5.5.4 DISTRIBUTION, MARKETING, AND SALES 102
5.5.5 RETAILERS 102
5.5.6 POST-SALES SERVICES 102
5.6 SUPPLY CHAIN ANALYSIS 103
5.6.1 PROMINENT COMPANIES 103
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 104
5.6.3 END USERS 104
5.7 ECOSYSTEM ANALYSIS 104
5.8 INVESTMENT AND FUNDING SCENARIO 106
5.9 TECHNOLOGY ANALYSIS 107
5.9.1 KEY TECHNOLOGIES 107
5.9.2 COMPLEMENTARY TECHNOLOGIES 108
5.9.2.1 Immunohistochemistry 108
5.10 PATENT ANALYSIS 109
5.11 TRADE ANALYSIS 111
5.11.1 IMPORT DATA FOR HS CODE 382200 111
5.11.2 EXPORT DATA FOR HS CODE 382200 112
5.12 KEY CONFERENCES AND EVENTS, 2025-2026 112
5.13 CASE STUDY ANALYSIS 113
5.13.1 CASE STUDY 1: LOCALIZED STRATEGY TO TAP MARKET POTENTIAL IN EUROPE 113
5.13.2 CASE STUDY 2: ENHANCED COMPANY FOOTPRINT IN
COMPETITIVE INDIAN MARKET 114
5.13.3 CASE STUDY 3: CUSTOMER-CENTRIC DIFFERENTIATION FOR PRODUCT OPTIMIZATION AND PREMIUM PRICING 115
5.14 REGULATORY LANDSCAPE 115
5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 116
5.15 REGULATORY FRAMEWORK 118
5.15.1 NORTH AMERICA 118
5.15.1.1 US 118
5.15.1.2 Canada 120
5.15.2 EUROPE 120
5.15.3 ASIA PACIFIC 122
5.15.3.1 Japan 122
5.15.3.2 China 123
5.15.3.3 India 124
5.15.3.4 South Korea 124
5.15.3.5 Indonesia 125
5.15.3.6 Russia 126
5.15.4 MIDDLE EAST & AFRICA 126
5.15.4.1 Saudi Arabia 126
5.15.4.2 Africa 127
5.15.5 LATIN AMERICA 127
5.15.5.1 Mexico 127
5.15.5.2 Brazil 128
5.16 PORTER'S FIVE FORCES ANALYSIS 128
5.16.1 BARGAINING POWER OF SUPPLIERS 130
5.16.2 BARGAINING POWER OF BUYERS 130
5.16.3 THREAT OF NEW ENTRANTS 130
5.16.4 THREAT OF SUBSTITUTES 130
5.16.5 INTENSITY OF COMPETITIVE RIVALRY 130
5.17 KEY STAKEHOLDERS AND BUYING CRITERIA 131
5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS 131
5.17.2 BUYING CRITERIA 132
5.18 RECENT POLICY CHANGES IN US MARKET AND THEIR POTENTIAL IMPACT ON APPROVAL PROCESS 133
5.19 INFLUENCE OF TARIFFS ON SUPPLY CHAIN RESILIENCE OF MEDTECH COMPANIES 135
5.20 GROWTH OF DECENTRALIZED TESTING VS. ADOPTION OF COST-EFFECTIVE CENTRALIZED TESTING 136
5.21 IMPACT OF AI/GENERATIVE AI ON IN VITRO DIAGNOSTICS MARKET 138
5.21.1 INTRODUCTION 138
5.21.2 MARKET POTENTIAL OF AI IN IVD DEVICES 138
5.21.3 AI USE CASES 139
5.21.4 KEY COMPANIES IMPLEMENTING AI 140
5.21.5 FUTURE OF GENERATIVE AI IN IN VITRO DIAGNOSTICS MARKET 140
6 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 141
6.1 INTRODUCTION 142
6.2 REAGENTS & KITS 142
6.2.1 RISE IN TEST VOLUMES ACROSS CLINICAL LABS, HOSPITALS, AND POINT-OF-CARE SETTINGS TO AID GROWTH 142
6.3 INSTRUMENTS 146
6.3.1 GROWING TREND OF AUTOMATION TO DRIVE MARKET 146
6.4 DATA MANAGEMENT SOFTWARE & SERVICES 151
6.4.1 INCREASING SHIFT TOWARD CLOUD-BASED PLATFORMS AND REMOTE DATA ACCESS TO STIMULATE GROWTH 151
7 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 156
7.1 INTRODUCTION 157
7.2 IMMUNOASSAYS 157
7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA) 162
7.2.1.1 Increasing use of immunoassays in cancer, infectious disease testing, and therapeutic drug monitoring to aid growth 162
7.2.2 CHEMILUMINESCENCE IMMUNOASSAYS 166
7.2.2.1 Need for minimal human intervention to support growth 166
7.2.3 IMMUNOFLUORESCENCE ASSAYS 171
7.2.3.1 Growing introduction of innovative diagnostic platforms to drive market 171
7.2.4 RAPID TESTS 174
7.2.4.1 Need for rapid diagnostic tests to expedite growth 174
7.2.5 ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT) 178
7.2.5.1 Need for early detection and monitoring of immune-related disorders to amplify growth 178
7.2.6 WESTERN BLOTTING 182
7.2.6.1 Increasing focus on biomarker discovery and personalized treatment to advance growth 182
7.2.7 OTHER IMMUNOASSAY TECHNOLOGIES 185
7.3 CLINICAL CHEMISTRY 188
7.3.1 BASIC METABOLIC PANELS 194
7.3.1.1 Increasing incidence of diabetes, kidney disorders, and hypertension to promote growth 194
7.3.2 LIVER PANELS 197
7.3.2.1 Rising prevalence of cirrhosis and viral hepatitis to foster growth 197
7.3.3 RENAL PROFILES 201
7.3.3.1 Growing awareness for preventive health check-ups to boost market 201
7.3.4 LIPID PROFILES 204
7.3.4.1 Rising prevalence of obesity to accelerate growth 204
7.3.5 THYROID FUNCTION PROFILES 208
7.3.5.1 High incidence of thyroid-related disorders to support growth 208
7.3.6 ELECTROLYTE PANELS 211
7.3.6.1 Growing shift toward home care and remote patient monitoring to fuel market 211
7.3.7 SPECIALTY CHEMICAL TESTS 215
7.3.7.1 Rising demand for specialized tests to contribute to growth 215
7.4 MOLECULAR DIAGNOSTICS 218
7.4.1 POLYMERASE CHAIN REACTION 223
7.4.1.1 High accuracy and speed in detecting pathogens to aid growth 223
7.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 227
7.4.2.1 Growing focus on rapid, onsite molecular diagnostics to propel market 227
7.4.3 DNA SEQUENCING & NEXT-GENERATION SEQUENCING 231
7.4.3.1 Growing applications in research, drug discovery, and molecular diagnostics to boost market 231
7.4.4 IN SITU HYBRIDIZATION 235
7.4.4.1 Rising prevalence of cancer and genetic disorders to assist growth 235
7.4.5 DNA MICROARRAYS 238
7.4.5.1 High resolution and throughput capabilities to favor growth 238
7.4.6 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES 241
7.5 GLUCOSE MONITORING 244
7.5.1 ONGOING TECHNOLOGICAL ADVANCEMENTS IN BLOOD GLUCOSE SELF-MONITORING DEVICES TO AID GROWTH 244
7.6 HEMATOLOGY 248
7.6.1 GROWING FOCUS ON STEM CELL RESEARCH TO BOOST MARKET 248
7.7 MICROBIOLOGY 251
7.7.1 RISING PREVALENCE OF MICROBIAL INFECTIONS TO SUSTAIN GROWTH 251
7.8 COAGULATION & HEMOSTASIS 254
7.8.1 GROWING CASES OF PULMONARY EMBOLISM, HEMOPHILIA, LIVER DISEASES TO DRIVE MARKET 254
7.9 BLOOD GAS ANALYZERS 258
7.9.1 GROWING SURGICAL INTERVENTIONS AND RISE IN ELDERLY POPULATION TO FUEL MARKET 258
7.10 URINALYSIS 262
7.10.1 RISING INCIDENCE OF URINARY TRACT INFECTIONS TO SUPPORT GROWTH 262
7.11 CHROMATOGRAPHY & MASS SPECTROMETRY 265
7.11.1 INCREASING APPLICATIONS IN DISEASE SCREENING AND DIAGNOSTICS TO AID GROWTH 265
8 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN 270
8.1 INTRODUCTION 271
8.2 BLOOD, SERUM, AND PLASMA SPECIMENS 271
8.2.1 GROWING SHIFT TOWARD DECENTRALIZED TESTING TO PROPEL MARKET 271
8.3 SALIVA SPECIMENS 275
8.3.1 GROWING ADVANCEMENTS IN MOLECULAR DIAGNOSTICS
TO BOOST MARKET 275
8.4 URINE SPECIMENS 278
8.4.1 RISING INCIDENCE OF URINARY TRACT INFECTIONS TO ACCELERATE GROWTH 278
8.5 OTHER SPECIMENS 282
9 IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING 286
9.1 INTRODUCTION 287
9.2 LABORATORY TESTS 287
9.2.1 INCREASING FOCUS ON EARLY AND ACCURATE DISEASE DETECTION TO ENCOURAGE GROWTH 287
9.3 POINT-OF-CARE TESTS 293
9.3.1 RISING DEMAND FOR DECENTRALIZED HEALTHCARE TO CONTRIBUTE TO GROWTH 293
10 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION 299
10.1 INTRODUCTION 300
10.2 INFECTIOUS DISEASES 301
10.2.1 INCREASING PREVALENCE OF VIRAL, BACTERIAL, AND PARASITIC INFECTIONS TO PROMOTE GROWTH 301
10.3 ONCOLOGY 304
10.3.1 RISING GLOBAL BURDEN OF CANCER TO EXPEDITE GROWTH 304
10.4 ENDOCRINOLOGY 308
10.4.1 INCREASING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO BOLSTER GROWTH 308
10.5 CARDIOLOGY 312
10.5.1 GROWING USE OF IMMUNOASSAYS IN CARDIOVASCULAR DISEASE DETECTION TO DRIVE MARKET 312
10.6 BLOOD SCREENING 315
10.6.1 RISING INCIDENCE OF HIV AND SYPHILIS TO SUPPORT GROWTH 315
10.7 GENETIC TESTING 319
10.7.1 INCREASING CLINICAL UTILITY OF GENETIC TESTS ACROSS ONCOLOGY, RARE DISEASES, AND REPRODUCTIVE HEALTH TO FOSTER GROWTH 319
10.8 AUTOIMMUNE DISEASES 322
10.8.1 RISE IN AUTOIMMUNE CONDITIONS GLOBALLY TO FACILITATE GROWTH 322
10.9 ALLERGY DIAGNOSTICS 326
10.9.1 INCREASING AWARENESS ABOUT ALLERGIES TO AMPLIFY GROWTH 326
10.10 DRUG MONITORING & TESTING 330
10.10.1 INCREASING ILLICIT DRUG CONSUMPTION TO SUSTAIN GROWTH 330
10.11 BONE & MINERAL DISORDERS 334
10.11.1 RISING CASES OF OSTEOPOROSIS TO FUEL MARKET 334
10.12 COAGULATION TESTING 338
10.12.1 INCREASING PREVALENCE OF HEMOPHILIA TO ADVANCE GROWTH 338
10.13 BLOOD GROUP TYPING 341
10.13.1 RISING NUMBER OF SURGICAL PROCEDURES TO SPEED UP GROWTH 341
10.14 OTHER APPLICATIONS 345
11 IN VITRO DIAGNOSTICS MARKET, BY END USER 349
11.1 INTRODUCTION 350
11.2 HOSPITALS & CLINICS 350
11.2.1 EXPANDING HEALTHCARE INFRASTRUCTURE TO SPEED UP GROWTH 350
11.3 CLINICAL LABORATORIES 354
11.3.1 LARGE REFERENCE LABORATORIES 358
11.3.1.1 Growing test volume and complexity of diagnostic testing to propel market 358
11.3.2 SMALL AND MEDIUM-SIZED LABORATORIES 361
11.3.2.1 Increasing shift toward community-based and point-of-care settings to foster growth 361
11.4 BLOOD BANKS 364
11.4.1 NEED TO ADDRESS PUBLIC HEALTH AND SAFETY CHALLENGES TO AID GROWTH 364
11.5 HOME CARE SETTINGS 368
11.5.1 GROWING INCLINATION TOWARD SELF-DIAGNOSIS AND MONITORING TO BOOST MARKET 368
11.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 372
11.6.1 INCREASING USE OF IVD PRODUCTS IN CLINICAL DRUG DEVELOPMENT AND COMPANION DIAGNOSTICS TO DRIVE MARKET 372
?
11.7 ACADEMIC INSTITUTES 375
11.7.1 RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO AUGMENT GROWTH 375
11.8 OTHER END USERS 378
12 IN VITRO DIAGNOSTICS MARKET, BY REGION 382
12.1 INTRODUCTION 383
12.2 NORTH AMERICA 383
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 384
12.2.2 US 392
12.2.2.1 Established reimbursement framework and favorable policies for IVD providers to drive market 392
12.2.3 CANADA 399
12.2.3.1 Favorable funding initiatives for early disease diagnosis to fuel market 399
12.3 EUROPE 405
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 406
12.3.2 GERMANY 413
12.3.2.1 Increasing investments in clinical diagnostics research to aid growth 413
12.3.3 FRANCE 418
12.3.3.1 High healthcare expenditure and rising investments in genomic medicine to drive market 418
12.3.4 UK 424
12.3.4.1 Rising adoption of genome-based testing to encourage growth 424
12.3.5 ITALY 430
12.3.5.1 Growing geriatric population and subsequent rise in chronic conditions to boost market 430
12.3.6 SPAIN 436
12.3.6.1 Increasing adoption of technologically advanced immunoassay systems to expedite growth 436
12.3.7 RUSSIA 441
12.3.7.1 High incidence of respiratory infectious diseases to boost market 441
12.3.8 SWITZERLAND 447
12.3.8.1 Growing prevalence of chronic diseases to propel market 447
12.3.9 REST OF EUROPE 453
12.4 ASIA PACIFIC 459
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 460
12.4.2 JAPAN 468
12.4.2.1 Increasing research investments for immunoassays to encourage growth 468
12.4.3 CHINA 473
12.4.3.1 Growing focus on preventive care to boost market 473
12.4.4 INDIA 479
12.4.4.1 Rising incidence of diabetes and cancer to augment growth 479
12.4.5 SOUTH KOREA 485
12.4.5.1 Rising healthcare spending for innovative IVD technologies to amplify growth 485
12.4.6 AUSTRALIA 491
12.4.6.1 Increasing incidence of chronic diseases and rising blood donations to fuel market 491
12.4.7 SINGAPORE 497
12.4.7.1 Rising technological advancements and automation to stimulate growth 497
12.4.8 REST OF ASIA PACIFIC 502
12.5 LATIN AMERICA 508
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 508
12.5.2 BRAZIL 514
12.5.2.1 Rising prevalence of diabetes to sustain growth 514
12.5.3 MEXICO 520
12.5.3.1 Growing establishment of clinical laboratories to fuel market 520
12.5.4 REST OF LATIN AMERICA 526
12.6 MIDDLE EAST & AFRICA 533
12.6.1 GROWING FOCUS ON PRENATAL AND CANCER TESTING TO DRIVE MARKET 533
12.6.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 533
12.7 GCC COUNTRIES 538
12.7.1 GCC COUNTRIES: MACROECONOMIC OUTLOOK 539
12.7.2 SAUDI ARABIA 544
12.7.2.1 Rising government healthcare expenditure to boost market 544
12.7.3 UAE 550
12.7.3.1 Improvements in healthcare infrastructure to support growth 550
12.7.4 OTHER GCC COUNTRIES 555
13 COMPETITIVE LANDSCAPE 561
13.1 OVERVIEW 561
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 561
13.3 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 562
13.4 REVENUE ANALYSIS, 2022-2024 563
13.5 MARKET SHARE ANALYSIS, 2024 564
13.6 COMPANY VALUATION AND FINANCIAL METRICS 566
13.7 BRAND/PRODUCT COMPARISON 567
13.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 568
13.8.1 STARS 568
13.8.2 EMERGING LEADERS 568
13.8.3 PERVASIVE PLAYERS 568
13.8.4 PARTICIPANTS 568
13.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 570
13.8.5.1 Company footprint 570
13.8.5.2 Region footprint 571
13.8.5.3 Product & service footprint 572
13.8.5.4 Technology footprint 573
13.8.5.5 End-user footprint 574
13.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 575
13.9.1 PROGRESSIVE COMPANIES 575
13.9.2 RESPONSIVE COMPANIES 575
13.9.3 DYNAMIC COMPANIES 575
13.9.4 STARTING BLOCKS 575
13.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 577
13.9.5.1 Detailed list of key startups/SMEs 577
13.9.5.2 Competitive benchmarking of key startups/SMEs 578
13.10 COMPETITIVE SCENARIO 579
13.10.1 PRODUCT LAUNCHES AND APPROVALS 579
13.10.2 DEALS 580
13.10.3 EXPANSIONS 581
13.11 POTENTIAL FUTURISTIC STRATEGIES OF LEADING PLAYERS OPERATING IN IVD MARKET 582
13.11.1 PRODUCT LAUNCHES AND APPROVALS 583
13.11.2 DEALS 583
14 COMPANY PROFILES 585
14.1 KEY PLAYERS 585
14.1.1 DANAHER 585
14.1.1.1 Business overview 585
14.1.1.2 Products/Services offered 587
14.1.1.3 Recent developments 590
14.1.1.3.1 Product launches and approvals 590
14.1.1.3.2 Deals 591
14.1.1.3.3 Expansions 592
14.1.1.4 MnM view 593
14.1.1.4.1 Key strengths 593
14.1.1.4.2 Strategic choices 593
14.1.1.4.3 Weaknesses and competitive threats 593
14.1.2 F. HOFFMANN-LA ROCHE LTD 594
14.1.2.1 Business overview 594
14.1.2.2 Products/Services offered 596
14.1.2.3 Recent developments 599
14.1.2.3.1 Product launches and approvals 599
14.1.2.3.2 Deals 601
14.1.2.3.3 Expansions 602
14.1.2.4 MnM view 602
14.1.2.4.1 Key strengths 602
14.1.2.4.2 Strategic choices 602
14.1.2.4.3 Weaknesses and competitive threats 602
14.1.3 ABBOTT 603
14.1.3.1 Business overview 603
14.1.3.2 Products/Services offered 604
14.1.3.3 Recent developments 607
14.1.3.3.1 Product launches and approvals 607
14.1.3.3.2 Deals 608
14.1.3.3.3 Expansions 609
14.1.3.4 MnM view 609
14.1.3.4.1 Key strengths 609
14.1.3.4.2 Strategic choices 609
14.1.3.4.3 Weakness and competitive threats 609
14.1.4 SIEMENS HEALTHINEERS AG 610
14.1.4.1 Business overview 610
14.1.4.2 Products/Services offered 612
14.1.4.3 Recent developments 614
14.1.4.3.1 Product launches and approvals 614
14.1.4.3.2 Deals 614
14.1.4.3.3 Expansions 616
14.1.4.4 MnM view 616
14.1.4.4.1 Key strengths 616
14.1.4.4.2 Strategic choices 616
14.1.4.4.3 Weaknesses and competitive threats 616
14.1.5 THERMO FISHER SCIENTIFIC INC. 617
14.1.5.1 Business overview 617
14.1.5.2 Products/Services offered 618
14.1.5.3 Recent developments 621
14.1.5.3.1 Product launches and approvals 621
14.1.5.3.2 Deals 622
14.1.5.3.3 Expansions 624
14.1.5.4 MnM view 624
14.1.5.4.1 Key strengths 624
14.1.5.4.2 Strategic choices 624
14.1.5.4.3 Weaknesses and competitive threats 625
14.1.6 ILLUMINA, INC. 626
14.1.6.1 Business overview 626
14.1.6.2 Products/Services offered 628
14.1.6.3 Recent developments 629
14.1.6.3.1 Product launches and approvals 629
14.1.6.3.2 Deals 630
14.1.6.3.3 Expansions 631
14.1.6.3.4 Other developments 632
14.1.7 HOLOGIC, INC. 633
14.1.7.1 Business overview 633
14.1.7.2 Products/Services offered 634
14.1.7.3 Recent developments 635
14.1.7.3.1 Product launches and approvals 635
14.1.7.3.2 Deals 636
14.1.7.3.3 Expansions 637
14.1.8 BIO-RAD LABORATORIES, INC. 638
14.1.8.1 Business overview 638
14.1.8.2 Products/Services offered 640
14.1.8.3 Recent developments 642
14.1.8.3.1 Product launches and approvals 642
14.1.8.3.2 Deals 643
14.1.9 BIOMERIEUX 644
14.1.9.1 Business overview 644
14.1.9.2 Products/Services offered 646
14.1.9.3 Recent developments 648
14.1.9.3.1 Product launches and approvals 648
14.1.9.3.2 Deals 649
14.1.9.3.3 Expansions 650
14.1.10 SYSMEX CORPORATION 651
14.1.10.1 Business overview 651
14.1.10.2 Products/Services offered 653
14.1.10.3 Recent developments 654
14.1.10.3.1 Product launches and approvals 654
14.1.10.3.2 Deals 655
14.1.10.3.3 Expansions 656
14.1.11 REVVITY 657
14.1.11.1 Business overview 657
14.1.11.2 Products/Services offered 659
14.1.11.3 Recent developments 660
14.1.11.3.1 Product launches and approvals 660
14.1.11.3.2 Deals 661
14.1.11.3.3 Other developments 661
14.1.12 BECTON, DICKINSON AND COMPANY 662
14.1.12.1 Business overview 662
14.1.12.2 Products/Services offered 663
14.1.12.3 Recent developments 666
14.1.12.3.1 Product launches and approvals 666
14.1.12.3.2 Deals 666
14.1.12.3.3 Expansions 667
14.1.13 AGILENT TECHNOLOGIES, INC. 668
14.1.13.1 Business overview 668
14.1.13.2 Products/Services offered 670
14.1.13.3 Recent developments 672
14.1.13.3.1 Product launches and approvals 672
14.1.13.3.2 Deals 673
14.1.13.3.3 Other developments 674
14.1.14 QIAGEN 675
14.1.14.1 Business overview 675
14.1.14.2 Products/Services offered 677
14.1.14.3 Recent developments 680
14.1.14.3.1 Product launches and approvals 680
14.1.14.3.2 Deals 682
14.1.15 DIASORIN S.P.A. 683
14.1.15.1 Business overview 683
14.1.15.2 Products/Services offered 685
14.1.15.3 Recent developments 687
14.1.15.3.1 Product launches and approvals 687
14.1.15.3.2 Deals 688
14.1.16 GRIFOLS, S.A. 689
14.1.16.1 Business overview 689
14.1.16.2 Products/Services offered 691
14.1.16.3 Recent developments 691
14.1.16.3.1 Product launches and approvals 691
14.1.16.3.2 Deals 692
14.1.17 WERFEN 693
14.1.17.1 Business overview 693
14.1.17.2 Products/Services offered 695
14.1.17.2.1 Deals 696
14.1.17.2.2 Expansions 697
14.1.18 QUIDELORTHO CORPORATION 698
14.1.18.1 Business overview 698
14.1.18.2 Products/Services offered 700
14.1.18.3 Recent developments 702
14.1.18.3.1 Product launches and approvals 702
14.1.18.3.2 Deals 703
14.1.18.3.3 Expansions 703
14.2 OTHER PLAYERS 704
14.2.1 DEVYSER 704
14.2.2 BIOSYNEX SA 705
14.2.3 SURMODICS, INC. 706
14.2.4 MENARINI SILICON BIOSYSTEMS 707
14.2.5 SPEEDX PTY. LTD. 708
14.2.6 GENSPEED BIOTECH GMBH 709
14.2.7 MERCK KGAA 710
14.2.8 CARIS LIFE SCIENCES 712
14.2.9 ARKRAY, INC. 713
14.2.10 ACCELERATE DIAGNOSTICS, INC. 714
14.2.11 CELLABS 715
14.2.12 J. MITRA & CO. PVT. LTD. 716
14.2.13 EPITOPE DIAGNOSTICS, INC. 717
14.2.14 BOSTER BIOLOGICAL TECHNOLOGY 718
14.2.15 ENZO BIOCHEM INC. 719
14.2.16 GENETIC SIGNATURES 720
14.2.17 SAVYON DIAGNOSTICS 721
14.2.18 TRIVITRON HEALTHCARE 722
14.2.19 MDXHEALTH 723
14.2.20 CREATIVE DIAGNOSTICS 724
14.2.21 INBIOS INTERNATIONAL, INC. 725
14.2.22 MACCURA BIOTECHNOLOGY CO., LTD. 726
14.2.23 LUYE LIFE SCIENCES GROUP 727
15 APPENDIX 728
15.1 DISCUSSION GUIDE 728
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 735
15.3 CUSTOMIZATION OPTIONS 737
15.4 RELATED REPORTS 738
15.5 AUTHOR DETAILS 739
TABLE 1 IN VITRO DIAGNOSTICS MARKET: INCLUSIONS AND EXCLUSIONS 59
TABLE 2 IN VITRO DIAGNOSTICS MARKET: RISK ASSESSMENT 74
TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION, 2022?2050 87
TABLE 4 IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES, 2022?2024 89
TABLE 5 APPLICATION OF CANCER BIOMARKERS IN CLINICAL PRACTICE 92
TABLE 6 RECENT DEVELOPMENTS IN IVD MARKET, 2021-2023 95
TABLE 7 AVERAGE SELLING PRICE TREND OF IVD PRODUCTS, BY KEY PLAYER,
2022-2024 (USD) 99
TABLE 8 AVERAGE SELLING PRICE TREND OF CLINICAL CHEMISTRY ANALYZERS,
BY REGION, 2022-2024 (USD) 100
TABLE 9 AVERAGE SELLING PRICE TREND OF IVD PRODUCTS, BY TYPE, 2022-2024 (USD) 101
TABLE 10 IN VITRO DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 105
TABLE 11 IN VITRO DIAGNOSTICS MARKET: INNOVATIONS AND PATENT
REGISTRATIONS, 2022?2024 110
TABLE 12 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019-2024 (USD MILLION) 111
TABLE 13 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019-2024 (USD MILLION) 112
TABLE 14 IN VITRO DIAGNOSTICS MARKET: KEY CONFERENCES AND EVENTS, 2025?2026 112
TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 116
TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 116
TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 117
TABLE 18 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 117
TABLE 19 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 118
TABLE 20 US: CLASSIFICATION OF IVD DEVICES 118
TABLE 21 EUROPE: CLASSIFICATION OF IVD DEVICES 121
TABLE 22 JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN 123
TABLE 23 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 123
TABLE 24 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 123
TABLE 25 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 124
TABLE 26 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES 125
TABLE 27 RUSSIA: CLASSIFICATION OF IVD DEVICES 126
TABLE 28 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 126
TABLE 29 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 128
TABLE 30 IN VITRO DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS 129
TABLE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD PRODUCTS (%) 131
TABLE 32 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 132
TABLE 33 US: OVERVIEW OF CERTAIN KEY CATEGORIES OF IVD DEVICES 134
TABLE 34 TARIFF RATES IMPOSED BY US, AS OF APRIL 2025 135
TABLE 35 COMPARATIVE ANALYSIS OF CENTRALIZED VS. DECENTRALIZED TESTING 137
TABLE 36 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022-2030 (USD MILLION) 142
TABLE 37 IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION,
2022-2030 (USD MILLION) 144
TABLE 38 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS,
BY COUNTRY, 2022-2030 (USD MILLION) 144
TABLE 39 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022-2030 (USD MILLION) 145
TABLE 40 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS,
BY COUNTRY, 2022-2030 (USD MILLION) 145
TABLE 41 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS,
BY COUNTRY, 2022-2030 (USD MILLION) 146
TABLE 42 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS,
BY COUNTRY, 2022-2030 (USD MILLION) 146
TABLE 43 KEY IVD INSTRUMENTS AVAILABLE WORLDWIDE 147
TABLE 44 IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION,
2022-2030 (USD MILLION) 148
TABLE 45 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY COUNTRY, 2022-2030 (USD MILLION) 149
TABLE 46 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2030 (USD MILLION) 149
TABLE 47 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2030 (USD MILLION) 150
TABLE 48 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY COUNTRY, 2022-2030 (USD MILLION) 150
TABLE 49 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY COUNTRY, 2022-2030 (USD MILLION) 150
TABLE 50 KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE WORLDWIDE 152
TABLE 51 IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY REGION, 2022-2030 (USD MILLION) 153
TABLE 52 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022-2030 (USD MILLION) 153
TABLE 53 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022-2030 (USD MILLION) 154
TABLE 54 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022-2030 (USD MILLION) 154
TABLE 55 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022-2030 (USD MILLION) 155
TABLE 56 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022-2030 (USD MILLION) 155
TABLE 57 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 157
TABLE 58 KEY IMMUNOASSAY ANALYZERS AVAILABLE WORLDWIDE 158
TABLE 59 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,
2022-2030 (USD MILLION) 159
TABLE 60 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION,
2022-2030 (USD MILLION) 160
TABLE 61 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2022-2030 (USD MILLION) 160
TABLE 62 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 161
TABLE 63 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 161
TABLE 64 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2022-2030 (USD MILLION) 162
TABLE 65 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2022-2030 (USD MILLION) 162
TABLE 66 KEY ELISA ANALYZERS AVAILABLE WORLDWIDE 163
TABLE 67 IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY REGION, 2022-2030 (USD MILLION) 164
TABLE 68 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 164
TABLE 69 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 165
TABLE 70 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 165
TABLE 71 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 166
TABLE 72 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 166
TABLE 73 KEY CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE WORLDWIDE 168
TABLE 74 IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS,
BY REGION, 2022-2030 (USD MILLION) 168
TABLE 75 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 169
TABLE 76 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 169
TABLE 77 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 170
TABLE 78 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 170
TABLE 79 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 171
TABLE 80 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS,
BY REGION, 2022-2030 (USD MILLION) 172
TABLE 81 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 172
TABLE 82 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 173
TABLE 83 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 173
TABLE 84 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 174
TABLE 85 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 174
TABLE 86 KEY RAPID TESTS AVAILABLE WORLDWIDE 175
TABLE 87 IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY REGION,
2022-2030 (USD MILLION) 176
TABLE 88 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS,
BY COUNTRY, 2022-2030 (USD MILLION) 176
TABLE 89 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY,
2022-2030 (USD MILLION) 177
TABLE 90 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022-2030 (USD MILLION) 177
TABLE 91 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022-2030 (USD MILLION) 178
TABLE 92 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS,
BY COUNTRY, 2022-2030 (USD MILLION) 178
TABLE 93 IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS,
BY REGION, 2022-2030 (USD MILLION) 179
TABLE 94 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 180
TABLE 95 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 180
TABLE 96 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 181
TABLE 97 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 181
TABLE 98 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION) 182
TABLE 99 KEY WESTERN BLOTTING SYSTEMS AVAILABLE WORLDWIDE 183
TABLE 100 IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY REGION,
2022-2030 (USD MILLION) 183
TABLE 101 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING,
BY COUNTRY, 2022-2030 (USD MILLION) 183
TABLE 102 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022-2030 (USD MILLION) 184
TABLE 103 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING,
BY COUNTRY, 2022-2030 (USD MILLION) 184
TABLE 104 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING,
BY COUNTRY, 2022-2030 (USD MILLION) 185
TABLE 105 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING,
BY COUNTRY, 2022-2030 (USD MILLION) 185
TABLE 106 IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES,
BY REGION, 2022-2030 (USD MILLION) 186
TABLE 107 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION) 186
TABLE 108 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION) 187
TABLE 109 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION) 187
TABLE 110 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION) 188
TABLE 111 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION) 188
TABLE 112 CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES AVAILABLE WORLDWIDE 189
TABLE 113 CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES AVAILABLE WORLDWIDE 190
TABLE 114 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE,
2022-2030 (USD MILLION) 191
TABLE 115 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY REGION,
2022-2030 (USD MILLION) 191
TABLE 116 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,
BY COUNTRY, 2022-2030 (USD MILLION) 192
TABLE 117 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,
BY COUNTRY, 2022-2030 (USD MILLION) 192
TABLE 118 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,
BY COUNTRY, 2022-2030 (USD MILLION) 193
TABLE 119 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,
BY COUNTRY, 2022-2030 (USD MILLION) 193
TABLE 120 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,
BY COUNTRY, 2022-2030 (USD MILLION) 194
TABLE 121 IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY REGION, 2022-2030 (USD MILLION) 195
TABLE 122 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022-2030 (USD MILLION) 195
TABLE 123 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS,
BY COUNTRY, 2022-2030 (USD MILLION) 196
TABLE 124 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS,
BY COUNTRY, 2022-2030 (USD MILLION) 196
TABLE 125 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022-2030 (USD MILLION) 197
TABLE 126 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022-2030 (USD MILLION) 197
TABLE 127 IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY REGION,
2022-2030 (USD MILLION) 198
TABLE 128 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS,
BY COUNTRY, 2022-2030 (USD MILLION) 199
TABLE 129 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022-2030 (USD MILLION) 199
TABLE 130 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022-2030 (USD MILLION) 200
TABLE 131 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS,
BY COUNTRY, 2022-2030 (USD MILLION) 200
TABLE 132 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS,
BY COUNTRY, 2022-2030 (USD MILLION) 201
TABLE 133 IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY REGION,
2022-2030 (USD MILLION) 202
TABLE 134 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES,
BY COUNTRY, 2022-2030 (USD MILLION) 202
TABLE 135 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022-2030 (USD MILLION) 203
TABLE 136 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES,
BY COUNTRY, 2022-2030 (USD MILLION) 203
TABLE 137 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES,
BY COUNTRY, 2022-2030 (USD MILLION) 204
TABLE 138 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES,
BY COUNTRY, 2022-2030 (USD MILLION) 204
TABLE 139 IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY REGION,
2022-2030 (USD MILLION) 205
TABLE 140 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES,
BY COUNTRY, 2022-2030 (USD MILLION) 206
TABLE 141 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022-2030 (USD MILLION) 206
TABLE 142 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022-2030 (USD MILLION) 207
TABLE 143 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES,
BY COUNTRY, 2022-2030 (USD MILLION) 207
TABLE 144 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES,
BY COUNTRY, 2022-2030 (USD MILLION) 208
TABLE 145 IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY REGION, 2022-2030 (USD MILLION) 209
TABLE 146 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022-2030 (USD MILLION) 209
TABLE 147 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES,
BY COUNTRY, 2022-2030 (USD MILLION) 210
TABLE 148 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022-2030 (USD MILLION) 210
TABLE 149 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022-2030 (USD MILLION) 211
TABLE 150 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022-2030 (USD MILLION) 211
TABLE 151 REFERENCE RANGES AND ABNORMAL CONDITIONS FOR KEY ELECTROLYTES 212
TABLE 152 IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY REGION,
2022-2030 (USD MILLION) 213
TABLE 153 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS,
BY COUNTRY, 2022-2030 (USD MILLION) 213
TABLE 154 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS,
BY COUNTRY, 2022-2030 (USD MILLION) 214
TABLE 155 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS,
BY COUNTRY, 2022-2030 (USD MILLION) 214
TABLE 156 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS,
BY COUNTRY, 2022-2030 (USD MILLION) 215
TABLE 157 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS,
BY COUNTRY, 2022-2030 (USD MILLION) 215
TABLE 158 IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY REGION, 2022-2030 (USD MILLION) 216
TABLE 159 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022-2030 (USD MILLION) 216
TABLE 160 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS,
BY COUNTRY, 2022-2030 (USD MILLION) 217
TABLE 161 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022-2030 (USD MILLION) 217
TABLE 162 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022-2030 (USD MILLION) 218
TABLE 163 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022-2030 (USD MILLION) 218
TABLE 164 KEY AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE WORLDWIDE 219
TABLE 165 IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION) 220
TABLE 166 IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2022-2030 (USD MILLION) 220
TABLE 167 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION) 221
TABLE 168 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY COUNTRY, 2022-2030 (USD MILLION) 221
TABLE 169 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY COUNTRY, 2022-2030 (USD MILLION) 222
TABLE 170 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION) 222
TABLE 171 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION) 223
TABLE 172 KEY POLYMERASE CHAIN REACTION INSTRUMENTS AVAILABLE WORLDWIDE 224
TABLE 173 IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022-2030 (USD MILLION) 225
TABLE 174 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2030 (USD MILLION) 225
TABLE 175 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2022-2030 (USD MILLION) 226
TABLE 176 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2030 (USD MILLION) 226
TABLE 177 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2030 (USD MILLION) 227
TABLE 178 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2030 (USD MILLION) 227
TABLE 179 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY INSTRUMENTS AVAILABLE WORLDWIDE 229
TABLE 180 IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2022-2030 (USD MILLION) 229
TABLE 181 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2030 (USD MILLION) 229
TABLE 182 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2030 (USD MILLION) 230
TABLE 183 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2030 (USD MILLION) 230
TABLE 184 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2030 (USD MILLION) 231
TABLE 185 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2030 (USD MILLION) 231
TABLE 186 KEY NEXT-GENERATION SEQUENCING-BASED INSTRUMENTS
AVAILABLE WORLDWIDE 232
TABLE 187 IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2022-2030 (USD MILLION) 233
TABLE 188 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2030 (USD MILLION) 233
TABLE 189 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2030 (USD MILLION) 234
TABLE 190 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2030 (USD MILLION) 234
TABLE 191 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2030 (USD MILLION) 235
TABLE 192 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2030 (USD MILLION) 235
TABLE 193 IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION,
2022-2030 (USD MILLION) 236
TABLE 194 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,
BY COUNTRY, 2022-2030 (USD MILLION) 236
TABLE 195 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,
BY COUNTRY, 2022-2030 (USD MILLION) 237
TABLE 196 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,
BY COUNTRY, 2022-2030 (USD MILLION) 237
TABLE 197 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,
BY COUNTRY, 2022-2030 (USD MILLION) 238
TABLE 198 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,
BY COUNTRY, 2022-2030 (USD MILLION) 238
TABLE 199 IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION,
2022-2030 (USD MILLION) 239
TABLE 200 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS,
BY COUNTRY, 2022-2030 (USD MILLION) 239
TABLE 201 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022-2030 (USD MILLION) 240
TABLE 202 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS,
BY COUNTRY, 2022-2030 (USD MILLION) 240
TABLE 203 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS,
BY COUNTRY, 2022-2030 (USD MILLION) 241
TABLE 204 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS,
BY COUNTRY, 2022-2030 (USD MILLION) 241
TABLE 205 IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY REGION, 2022-2030 (USD MILLION) 242
TABLE 206 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION) 242
TABLE 207 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION) 243
TABLE 208 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION) 243
TABLE 209 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION) 244
TABLE 210 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION) 244
TABLE 211 DIABETES-RELATED HEALTH EXPENDITURE PER PERSON,
2021 VS. 2030 VS. 2045 (USD) 245
TABLE 212 IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY REGION,
2022-2030 (USD MILLION) 246
TABLE 213 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022-2030 (USD MILLION) 246
TABLE 214 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING,
BY COUNTRY, 2022-2030 (USD MILLION) 247
TABLE 215 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING,
BY COUNTRY, 2022-2030 (USD MILLION) 247
TABLE 216 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING,
BY COUNTRY, 2022-2030 (USD MILLION) 248
TABLE 217 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING,
BY COUNTRY, 2022-2030 (USD MILLION) 248
TABLE 218 IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY REGION,
2022-2030 (USD MILLION) 249
TABLE 219 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY,
BY COUNTRY, 2022-2030 (USD MILLION) 249
TABLE 220 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2030 (USD MILLION) 250
TABLE 221 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2030 (USD MILLION) 250
TABLE 222 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2030 (USD MILLION) 251
TABLE 223 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY,
BY COUNTRY, 2022-2030 (USD MILLION) 251
TABLE 224 IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY REGION,
2022-2030 (USD MILLION) 252
TABLE 225 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY,
BY COUNTRY, 2022-2030 (USD MILLION) 252
TABLE 226 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2030 (USD MILLION) 253
TABLE 227 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2030 (USD MILLION) 253
TABLE 228 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY,
BY COUNTRY, 2022-2030 (USD MILLION) 254
TABLE 229 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY,
BY COUNTRY, 2022-2030 (USD MILLION) 254
TABLE 230 IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY REGION, 2022-2030 (USD MILLION) 255
TABLE 231 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2030 (USD MILLION) 256
TABLE 232 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS,
BY COUNTRY, 2022-2030 (USD MILLION) 256
TABLE 233 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2030 (USD MILLION) 257
TABLE 234 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2030 (USD MILLION) 257
TABLE 235 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2030 (USD MILLION) 258
TABLE 236 KEY BLOOD GAS ANALYZERS AVAILABLE WORLDWIDE 259
TABLE 237 IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY REGION,
2022-2030 (USD MILLION) 259
TABLE 238 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022-2030 (USD MILLION) 260
TABLE 239 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS,
BY COUNTRY, 2022-2030 (USD MILLION) 260
TABLE 240 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS,
BY COUNTRY, 2022-2030 (USD MILLION) 261
TABLE 241 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS,
BY COUNTRY, 2022-2030 (USD MILLION) 261
TABLE 242 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZER,
BY COUNTRY, 2022-2030 (USD MILLION) 262
TABLE 243 IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY REGION,
2022-2030 (USD MILLION) 263
TABLE 244 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS,
BY COUNTRY, 2022-2030 (USD MILLION) 263
TABLE 245 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY,
2022-2030 (USD MILLION) 264
TABLE 246 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2030 (USD MILLION) 264
TABLE 247 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2030 (USD MILLION) 265
TABLE 248 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2030 (USD MILLION) 265
TABLE 249 IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY REGION, 2022-2030 (USD MILLION) 266
TABLE 250 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2030 (USD MILLION) 267
TABLE 251 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2030 (USD MILLION) 267
TABLE 252 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2030 (USD MILLION) 268
TABLE 253 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2030 (USD MILLION) 268
TABLE 254 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2030 (USD MILLION) 269
TABLE 255 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION) 271
TABLE 256 KEY BLOOD, SERUM, AND PLASMA SAMPLE TYPE-BASED
PRODUCTS AVAILABLE WORLDWIDE 272
TABLE 257 IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND
PLASMA SPECIMENS, BY REGION, 2022-2030 (USD MILLION) 273
TABLE 258 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION) 273
TABLE 259 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION) 274
TABLE 260 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION) 274
TABLE 261 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM,
AND PLASMA SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION) 275
TABLE 262 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM,
AND PLASMA SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION) 275
TABLE 263 IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY REGION,
2022-2030 (USD MILLION) 276
TABLE 264 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS,
BY COUNTRY, 2022-2030 (USD MILLION) 276
TABLE 265 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION) 277
TABLE 266 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS,
BY COUNTRY, 2022-2030 (USD MILLION) 277
TABLE 267 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS,
BY COUNTRY, 2022-2030 (USD MILLION) 278
TABLE 268 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS,
BY COUNTRY, 2022-2030 (USD MILLION) 278
TABLE 269 KEY URINE SAMPLE TYPE-BASED PRODUCTS AVAILABLE WORLDWIDE 279
TABLE 270 IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY REGION,
2022-2030 (USD MILLION) 280
TABLE 271 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS,
BY COUNTRY, 2022-2030 (USD MILLION) 280
TABLE 272 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION) 281
TABLE 273 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS,
BY COUNTRY, 2022-2030 (USD MILLION) 281
TABLE 274 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS,
BY COUNTRY, 2022-2030 (USD MILLION) 282
TABLE 275 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS,
BY COUNTRY, 2022-2030 (USD MILLION) 282
TABLE 276 IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY REGION,
2022-2030 (USD MILLION) 283
TABLE 277 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS,
BY COUNTRY, 2022-2030 (USD MILLION) 283
TABLE 278 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION) 284
TABLE 279 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS,
BY COUNTRY, 2022-2030 (USD MILLION) 284
TABLE 280 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS,
BY COUNTRY, 2022-2030 (USD MILLION) 285
TABLE 281 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS,
BY COUNTRY, 2022-2030 (USD MILLION) 285
TABLE 282 IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING, 2022-2030 (USD MILLION) 287
TABLE 283 IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY TECHNOLOGY, 2022-2030 (USD MILLION) 290
TABLE 284 IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY REGION,
2022-2030 (USD MILLION) 290
TABLE 285 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS,
BY COUNTRY, 2022-2030 (USD MILLION) 291
TABLE 286 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2030 (USD MILLION) 291
TABLE 287 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS,
BY COUNTRY, 2022-2030 (USD MILLION) 292
TABLE 288 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS,
BY COUNTRY, 2022-2030 (USD MILLION) 292
TABLE 289 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS,
BY COUNTRY, 2022-2030 (USD MILLION) 293
TABLE 290 IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY TECHNOLOGY, 2022-2030 (USD MILLION) 295
TABLE 291 IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY REGION,
2022-2030 (USD MILLION) 296
TABLE 292 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS,
BY COUNTRY, 2022-2030 (USD MILLION) 296
TABLE 293 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS,
BY COUNTRY, 2022-2030 (USD MILLION) 297
TABLE 294 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS,
BY COUNTRY, 2022-2030 (USD MILLION) 297
TABLE 295 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS,
BY COUNTRY, 2022-2030 (USD MILLION) 298
TABLE 296 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS,
BY COUNTRY, 2022-2030 (USD MILLION) 298
TABLE 297 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 300
TABLE 298 IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION,
2022-2030 (USD MILLION) 302
TABLE 299 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022-2030 (USD MILLION) 302
TABLE 300 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022-2030 (USD MILLION) 303
TABLE 301 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022-2030 (USD MILLION) 303
TABLE 302 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022-2030 (USD MILLION) 304
TABLE 303 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022-2030 (USD MILLION) 304
TABLE 304 INCREASING INCIDENCE OF CANCER, BY REGION, 2022 VS. 2040 305
TABLE 305 LIST OF APPROVED COMPANION DIAGNOSTIC DEVICES, 2022-2024 306
TABLE 306 IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION,
2022-2030 (USD MILLION) 306
TABLE 307 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY,
BY COUNTRY, 2022-2030 (USD MILLION) 306
TABLE 308 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY,
2022-2030 (USD MILLION) 307
TABLE 309 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2030 (USD MILLION) 307
TABLE 310 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2030 (USD MILLION) 308
TABLE 311 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2030 (USD MILLION) 308
TABLE 312 IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY REGION,
2022-2030 (USD MILLION) 309
TABLE 313 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY,
BY COUNTRY, 2022-2030 (USD MILLION) 310
TABLE 314 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022-2030 (USD MILLION) 310
TABLE 315 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY,
BY COUNTRY, 2022-2030 (USD MILLION) 311
TABLE 316 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY,
BY COUNTRY, 2022-2030 (USD MILLION) 311
TABLE 317 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY,
BY COUNTRY, 2022-2030 (USD MILLION) 312
TABLE 318 IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY REGION,
2022-2030 (USD MILLION) 313
TABLE 319 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY,
BY COUNTRY, 2022-2030 (USD MILLION) 313
TABLE 320 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY,
2022-2030 (USD MILLION) 314
TABLE 321 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022-2030 (USD MILLION) 314
TABLE 322 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022-2030 (USD MILLION) 315
TABLE 323 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY,
BY COUNTRY, 2022-2030 (USD MILLION) 315
TABLE 324 IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY REGION,
2022-2030 (USD MILLION) 316
TABLE 325 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING,
BY COUNTRY, 2022-2030 (USD MILLION) 317
TABLE 326 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2030 (USD MILLION) 317
TABLE 327 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING,
BY COUNTRY, 2022-2030 (USD MILLION) 318
TABLE 328 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING,
BY COUNTRY, 2022-2030 (USD MILLION) 318
TABLE 329 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING,
BY COUNTRY, 2022-2030 (USD MILLION) 319
TABLE 330 IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION,
2022-2030 (USD MILLION) 320
TABLE 331 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING,
BY COUNTRY, 2022-2030 (USD MILLION) 320
TABLE 332 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2030 (USD MILLION) 321
TABLE 333 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING,
BY COUNTRY, 2022-2030 (USD MILLION) 321
TABLE 334 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING,
BY COUNTRY, 2022-2030 (USD MILLION) 322
TABLE 335 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING,
BY COUNTRY, 2022-2030 (USD MILLION) 322
TABLE 336 IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY REGION,
2022-2030 (USD MILLION) 324
TABLE 337 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2030 (USD MILLION) 324
TABLE 338 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2022-2030 (USD MILLION) 325
TABLE 339 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2022-2030 (USD MILLION) 325
TABLE 340 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2022-2030 (USD MILLION) 326
TABLE 341 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2030 (USD MILLION) 326
TABLE 342 IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION,
2022-2030 (USD MILLION) 327
TABLE 343 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS,
BY COUNTRY, 2022-2030 (USD MILLION) 328
TABLE 344 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS,
BY COUNTRY, 2022-2030 (USD MILLION) 328
TABLE 345 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS,
BY COUNTRY, 2022-2030 (USD MILLION) 329
TABLE 346 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS,
BY COUNTRY, 2022-2030 (USD MILLION) 329
TABLE 347 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS,
BY COUNTRY, 2022-2030 (USD MILLION) 330
TABLE 348 KEY PRODUCTS FOR DRUG MONITORING WORLDWIDE 331
TABLE 349 KEY IVD PRODUCTS FOR DRUG TESTING WORLDWIDE 331
TABLE 350 IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2022-2030 (USD MILLION) 332
TABLE 351 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2030 (USD MILLION) 332
TABLE 352 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING,
BY COUNTRY, 2022-2030 (USD MILLION) 333
TABLE 353 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2030 (USD MILLION) 333
TABLE 354 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2030 (USD MILLION) 334
TABLE 355 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2030 (USD MILLION) 334
TABLE 356 KEY PRODUCTS FOR BONE & MINERAL DISORDERS WORLDWIDE 336
TABLE 357 IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2022-2030 (USD MILLION) 336
TABLE 358 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022-2030 (USD MILLION) 336
TABLE 359 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS,
BY COUNTRY, 2022-2030 (USD MILLION) 337
TABLE 360 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022-2030 (USD MILLION) 337
TABLE 361 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022-2030 (USD MILLION) 338
TABLE 362 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022-2030 (USD MILLION) 338
TABLE 363 IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY REGION,
2022-2030 (USD MILLION) 339
TABLE 364 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022-2030 (USD MILLION) 339
TABLE 365 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING,
BY COUNTRY, 2022-2030 (USD MILLION) 340
TABLE 366 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING,
BY COUNTRY, 2022-2030 (USD MILLION) 340
TABLE 367 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING,
BY COUNTRY, 2022-2030 (USD MILLION) 341
TABLE 368 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING,
BY COUNTRY, 2022-2030 (USD MILLION) 341
TABLE 369 IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY REGION,
2022-2030 (USD MILLION) 342
TABLE 370 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING,
BY COUNTRY, 2022-2030 (USD MILLION) 343
TABLE 371 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING,
BY COUNTRY, 2022-2030 (USD MILLION) 343
TABLE 372 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING,
BY COUNTRY, 2022-2030 (USD MILLION) 344
TABLE 373 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING,
BY COUNTRY, 2022-2030 (USD MILLION) 344
TABLE 374 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING,
BY COUNTRY, 2022-2030 (USD MILLION) 345
TABLE 375 IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION,
2022-2030 (USD MILLION) 346
TABLE 376 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022-2030 (USD MILLION) 346
TABLE 377 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022-2030 (USD MILLION) 347
TABLE 378 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022-2030 (USD MILLION) 347
TABLE 379 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022-2030 (USD MILLION) 348
TABLE 380 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022-2030 (USD MILLION) 348
TABLE 381 IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 350
TABLE 382 IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION,
2022-2030 (USD MILLION) 352
TABLE 383 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022-2030 (USD MILLION) 352
TABLE 384 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022-2030 (USD MILLION) 353
TABLE 385 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022-2030 (USD MILLION) 353
TABLE 386 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022-2030 (USD MILLION) 354
TABLE 387 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022-2030 (USD MILLION) 354
TABLE 388 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2022-2030 (USD MILLION) 355
TABLE 389 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022-2030 (USD MILLION) 355
TABLE 390 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION) 356
TABLE 391 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2022-2030 (USD MILLION) 356
TABLE 392 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2022-2030 (USD MILLION) 357
TABLE 393 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION) 357
TABLE 394 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION) 358
TABLE 395 IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY REGION, 2022-2030 (USD MILLION) 359
TABLE 396 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION) 359
TABLE 397 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION) 360
TABLE 398 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION) 360
TABLE 399 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION) 361
TABLE 400 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION) 361
TABLE 401 IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY REGION, 2022-2030 (USD MILLION) 362
TABLE 402 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION) 362
TABLE 403 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION) 363
TABLE 404 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION) 363
TABLE 405 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION) 364
TABLE 406 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION) 364
TABLE 407 IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY REGION,
2022-2030 (USD MILLION) 365
TABLE 408 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS,
BY COUNTRY, 2022-2030 (USD MILLION) 366
TABLE 409 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2030 (USD MILLION) 366
TABLE 410 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2030 (USD MILLION) 367
TABLE 411 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS,
BY COUNTRY, 2022-2030 (USD MILLION) 367
TABLE 412 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS,
BY COUNTRY, 2022-2030 (USD MILLION) 368
TABLE 413 IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION,
2022-2030 (USD MILLION) 369
TABLE 414 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022-2030 (USD MILLION) 370
TABLE 415 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022-2030 (USD MILLION) 370
TABLE 416 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022-2030 (USD MILLION) 371
TABLE 417 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022-2030 (USD MILLION) 371
TABLE 418 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022-2030 (USD MILLION) 372
TABLE 419 IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2030 (USD MILLION) 373
TABLE 420 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION) 373
TABLE 421 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION) 374
TABLE 422 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION) 374
TABLE 423 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION) 375
TABLE 424 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION) 375
TABLE 425 IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY REGION,
2022-2030 (USD MILLION) 376
TABLE 426 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2022-2030 (USD MILLION) 376
TABLE 427 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2022-2030 (USD MILLION) 377
TABLE 428 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2022-2030 (USD MILLION) 377
TABLE 429 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2022-2030 (USD MILLION) 378
TABLE 430 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2022-2030 (USD MILLION) 378
TABLE 431 IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION,
2022-2030 (USD MILLION) 379
TABLE 432 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2022-2030 (USD MILLION) 379
TABLE 433 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2030 (USD MILLION) 380
TABLE 434 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2022-2030 (USD MILLION) 380
TABLE 435 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2022-2030 (USD MILLION) 381
TABLE 436 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2022-2030 (USD MILLION) 381
TABLE 437 IN VITRO DIAGNOSTICS MARKET, BY REGION, 2022-2030 (USD MILLION) 383
TABLE 438 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 384
TABLE 439 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY,
2022-2030 (USD MILLION) 386
TABLE 440 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION) 386
TABLE 441 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2030 (USD MILLION) 387
TABLE 442 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION) 388
TABLE 443 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,
BY TYPE, 2022-2030 (USD MILLION) 388
TABLE 444 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION) 389
TABLE 445 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,
2022-2030 (USD MILLION) 389
TABLE 446 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,
2022-2030 (USD MILLION) 390
TABLE 447 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 390
TABLE 448 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER,
2022-2030 (USD MILLION) 391
TABLE 449 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION) 391
TABLE 450 US: KEY MACROECONOMIC INDICATORS 393
TABLE 451 US: NUMBER OF IN VITRO DIAGNOSTICS TESTS CONDUCTED,
2022-2030 (BILLION) 393
TABLE 452 US: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022-2030 (USD MILLION) 393
TABLE 453 US: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2030 (USD MILLION) 394
TABLE 454 US: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,
2022-2030 (USD MILLION) 394
TABLE 455 US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE,
2022-2030 (USD MILLION) 395
TABLE 456 US: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION) 395
TABLE 457 US: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION) 396
TABLE 458 US: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION) 396
TABLE 459 US: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 397
TABLE 460 US: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 398
TABLE 461 US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION) 398
TABLE 462 CANADA: ESTIMATED PREVALENCE OF DIABETES, 2024 VS. 2034 399
TABLE 463 CANADA: KEY MACROECONOMIC INDICATORS 400
TABLE 464 CANADA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022-2030 (USD MILLION) 400
TABLE 465 CANADA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2030 (USD MILLION) 401
TABLE 466 CANADA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,
2022-2030 (USD MILLION) 401
TABLE 467 CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION) 402
TABLE 468 CANADA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2022-2030 (USD MILLION) 402
TABLE 469 CANADA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,
2022-2030 (USD MILLION) 403
TABLE 470 CANADA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,
2022-2030 (USD MILLION) 403
TABLE 471 CANADA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 404
TABLE 472 CANADA: IN VITRO DIAGNOSTICS MARKET, BY END USER,
2022-2030 (USD MILLION) 404
TABLE 473 CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY TYPE, 2022-2030 (USD MILLION) 405
TABLE 474 EUROPE: KEY MACROECONOMIC INDICATORS 406
TABLE 475 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY,
2022-2030 (USD MILLION) 407
TABLE 476 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022-2030 (USD MILLION) 407
TABLE 477 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2030 (USD MILLION) 408
TABLE 478 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,
2022-2030 (USD MILLION) 408
TABLE 479 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION) 409
TABLE 480 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2022-2030 (USD MILLION) 409
TABLE 481 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,
2022-2030 (USD MILLION) 410
TABLE 482 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,
2022-2030 (USD MILLION) 410
TABLE 483 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 411
TABLE 484 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER,
2022-2030 (USD MILLION) 412
TABLE 485 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION) 412
TABLE 486 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022-2030 (USD MILLION) 414
TABLE 487 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2030 (USD MILLION) 414
TABLE 488 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION) 415
TABLE 489 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,
BY TYPE, 2022-2030 (USD MILLION) 415
TABLE 490 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2022-2030 (USD MILLION) 416
TABLE 491 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,
2022-2030 (USD MILLION) 416
TABLE 492 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,
2022-2030 (USD MILLION) 417
TABLE 493 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 417
TABLE 494 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY END USER,
2022-2030 (USD MILLION) 418
TABLE 495 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY TYPE, 2022-2030 (USD MILLION) 418
TABLE 496 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022-2030 (USD MILLION) 419
TABLE 497 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2030 (USD MILLION) 420
TABLE 498 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS,
BY TYPE, 2022-2030 (USD MILLION) 420
TABLE 499 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,
BY TYPE, 2022-2030 (USD MILLION) 421
TABLE 500 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2022-2030 (USD MILLION) 421
TABLE 501 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,
2022-2030 (USD MILLION) 422
TABLE 502 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,
2022-2030 (USD MILLION) 422
TABLE 503 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 423
TABLE 504 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY END USER,
2022-2030 (USD MILLION) 423
TABLE 505 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY TYPE, 2022-2030 (USD MILLION) 424
TABLE 506 UK: KEY MACROECONOMIC INDICATORS 425
TABLE 507 UK: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022-2030 (USD MILLION) 426
TABLE 508 UK: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2030 (USD MILLION) 426
TABLE 509 UK: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,
2022-2030 (USD MILLION) 427
TABLE 510 UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE,
2022-2030 (USD MILLION) 427
TABLE 511 UK: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION) 428
TABLE 512 UK: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION) 428
TABLE 513 UK: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION) 429
TABLE 514 UK: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 429
TABLE 515 UK: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 430
TABLE 516 UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION) 430
TABLE 517 ITALY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022-2030 (USD MILLION) 431
TABLE 518 ITALY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2030 (USD MILLION) 432
TABLE 519 ITALY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,
2022-2030 (USD MILLION) 432
TABLE 520 ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION) 433
TABLE 521 ITALY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION) 433
TABLE 522 ITALY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION) 434
TABLE 523 ITALY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION) 434
TABLE 524 ITALY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 435
TABLE 525 ITALY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 435
TABLE 526 ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION) 436
TABLE 527 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022-2030 (USD MILLION) 437
TABLE 528 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2030 (USD MILLION) 437
TABLE 529 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,
2022-2030 (USD MILLION) 438
TABLE 530 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION) 438
TABLE 531 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION) 439
TABLE 532 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,
2022-2030 (USD MILLION) 439
TABLE 533 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,
2022-2030 (USD MILLION) 440
TABLE 534 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 440
TABLE 535 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY END USER,
2022-2030 (USD MILLION) 441
TABLE 536 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION) 441
TABLE 537 RUSSIA: KEY MACROECONOMIC INDICATORS 442
TABLE 538 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022-2030 (USD MILLION) 442
TABLE 539 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2030 (USD MILLION) 443
TABLE 540 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,
2022-2030 (USD MILLION) 443
TABLE 541 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION) 444
TABLE 542 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2022-2030 (USD MILLION) 444
TABLE 543 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,
2022-2030 (USD MILLION) 445
TABLE 544 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,
2022-2030 (USD MILLION) 445
TABLE 545 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 446
TABLE 546 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY END USER,
2022-2030 (USD MILLION) 446
TABLE 547 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY TYPE, 2022-2030 (USD MILLION) 447
TABLE 548 SWITZERLAND: KEY MACROECONOMIC INDICATORS 448
TABLE 549 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022-2030 (USD MILLION) 448
TABLE 550 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2030 (USD MILLION) 449
TABLE 551 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION) 449
TABLE 552 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,
BY TYPE, 2022-2030 (USD MILLION) 450
TABLE 553 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION) 450
TABLE 554 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,
2022-2030 (USD MILLION) 451
TABLE 555 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,
2022-2030 (USD MILLION) 451
TABLE 556 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 452
TABLE 557 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY END USER,
2022-2030 (USD MILLION) 453
TABLE 558 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY TYPE, 2022-2030 (USD MILLION) 453
TABLE 559 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION) 454
TABLE 560 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2030 (USD MILLION) 455
TABLE 561 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS,
BY TYPE, 2022-2030 (USD MILLION) 455
TABLE 562 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,
BY TYPE, 2022-2030 (USD MILLION) 456
TABLE 563 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION) 456
TABLE 564 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,
2022-2030 (USD MILLION) 457
TABLE 565 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,
2022-2030 (USD MILLION) 457
TABLE 566 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 458
TABLE 567 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER,
2022-2030 (USD MILLION) 458
TABLE 568 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION) 459
TABLE 569 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 460
TABLE 570 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY,
2022-2030 (USD MILLION) 462
TABLE 571 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022-2030 (USD MILLION) 462
TABLE 572 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2030 (USD MILLION) 463
TABLE 573 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS,
BY TYPE, 2022-2030 (USD MILLION) 464
TABLE 574 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,
BY TYPE, 2022-2030 (USD MILLION) 464
TABLE 575 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2022-2030 (USD MILLION) 465
TABLE 576 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,
2022-2030 (USD MILLION) 465
TABLE 577 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,
2022-2030 (USD MILLION) 466
TABLE 578 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 466
TABLE 579 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER,
2022-2030 (USD MILLION) 467
TABLE 580 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY TYPE, 2022-2030 (USD MILLION) 467
TABLE 581 JAPAN: KEY MACROECONOMIC INDICATORS 468
TABLE 582 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022-2030 (USD MILLION) 469
TABLE 583 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2030 (USD MILLION) 469
TABLE 584 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,
2022-2030 (USD MILLION) 470
TABLE 585 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION) 470
TABLE 586 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION) 471
TABLE 587 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,
2022-2030 (USD MILLION) 471
TABLE 588 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,
2022-2030 (USD MILLION) 472
TABLE 589 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 472
TABLE 590 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY END USER,
2022-2030 (USD MILLION) 473
TABLE 591 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY TYPE, 2022-2030 (USD MILLION) 473
TABLE 592 CHINA: KEY MACROECONOMIC INDICATORS 474
TABLE 593 CHINA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022-2030 (USD MILLION) 474
TABLE 594 CHINA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2030 (USD MILLION) 475
TABLE 595 CHINA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,
2022-2030 (USD MILLION) 475
TABLE 596 CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION) 476
TABLE 597 CHINA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2022-2030 (USD MILLION) 476
TABLE 598 CHINA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,
2022-2030 (USD MILLION) 477
TABLE 599 CHINA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,
2022-2030 (USD MILLION) 477
TABLE 600 CHINA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 478
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security